Author(s)

Sha Zhen ¹

Affiliation(s)

¹ School of Shazhen, Shenyang Pharmaceutical University, Shenyang, China

Corresponding Author

Sha Zhen

ABSTRACT

The histone deacetylase (HDAC) is a kind of protease, which plays an important role in the modification of chromosome structure and the regulation of gene expression. However, its dysfunction has been proved to be directly related to the occurrence and development of many diseases (especially tumors). Histone deacetylase inhibitors can interfere with the function of histone deacetylase. Herein, the mechanism of action, advantages and disadvantages of histone deacetylase inhibitors, and the research progress of histone deacetylase inhibitors in tumor therapy are reviewed.

KEYWORDS

HDAC, tumors, Histone deacetylase inhibitors, progress

CITE THIS PAPER

Sha Zhen, Research progress of histone deacetylase inhibitors. MEDS Clinical Medicine (2022) Vol. 3: 7-12. DOI: http://dx.doi.org/10.23977/medsc.2022.030102.

REFERENCES

[1] LI Xian, DING Jie, et al. Research progress of histone deacetylase inhibitors and their deriving multitarget inhibitors in gastrointestinal cancer.
[2] Deng R, Zhang P, Liu W, et al. HDAC is indispensable for IFN-γ-induced B7-H1 expression in gastric cancer. ClinEpigenetics, 2018, 10(1): 153.
[3] DONG Zhao-ji, HAN Cheng, LIU Jing-jing, WANG Rui-luan, GU Wei, NIE Ai-hua1, et al. Histone deacetylase inhibitors: research advances.
[4] Yuan Z, Chen S, Sun Q, et al. Olaparib hydroxamic acid derivatives as dual PARP and HDAC inhibitors for cancer therapy. Bioorg Med Chem, 2017, 25(15):4100-4109.
[5] TAN Yu-mei, HUANG Wen-yuan, YU, Nie-fang, et al. Structure-activity relationships of histone deacetylase inhibitors.
[6] Eot-Houllier G, Fulcrand G, Magnaghi-Jaulin L, et al. Histone deacetylase inhibitors and genomic instability. Cancer Lett, 2009, 274: 169−176. 
[7] MacDonald JL, Roskams AJ. Epigenetic regulation of nervous system development by DNA methylation and histone deacetylation. P Neurobiol, 2009, 88:170−183. 
[8] Mai A, Rotili D, Tarantino D, et al. Identification of 4-hydroxyquinolines inhibitors of p300/CBP histone acetyltransferases. Bioorg Med Chem Lett, 2009, 19: 1132−1135.
[9] Gregoretti IV, Lee YM, Goodson HV. Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J Mol Biol, 2004, 338: 17−31.
[10] Li Y, Seto E. HDACs and HDAC Inhibitors in Cancer Development and Therapy. Cold Spring Harbor Perspectives in Medicine, 2016: a026831.
[11] Mai A, Massa S, Rotili D, et al. Exploring the connection unit in the HDAC inhibitor pharmacophore model: novel uracil-based hydroxamates. Bioorg Med Chem Lett, 2005, 15: 4656−4661.

Sponsors, Associates, and Links

---

• Journal of Neurobiology and Genetics
  
  
• Medical Imaging and Nuclear Medicine
  
  
• Bacterial Genetics and Ecology
  
  
• Transactions on Cancer
  
  
• Journal of Biophysics and Ecology
  
  
• Journal of Animal Science and Veterinary
  
  
• Academic Journal of Biochemistry and Molecular Biology
  
  
• Transactions on Cell and Developmental Biology
  
  
• Rehabilitation Engineering & Assistive Technology
  
  
• Orthopaedics and Sports Medicine
  
  
• Hematology and Stem Cell
  
  
• Journal of Intelligent Informatics and Biomedical Engineering
  
  
• MEDS Basic Medicine
  
  
• MEDS Stomatology
  
  
• MEDS Public Health and Preventive Medicine
  
  
• MEDS Chinese Medicine
  
  
• Journal of Enzyme Engineering
  
  
• Advances in Industrial Pharmacy and Pharmaceutical Sciences
  
  
• Bacteriology and Microbiology
  
  
• Advances in Physiology and Pathophysiology
  
  
• Journal of Vision and Ophthalmology
  
  
• Frontiers of Obstetrics and Gynecology
  
  
• Digestive Disease and Diabetes
  
  
• Advances in Immunology and Vaccines
  
  
• Nanomedicine and Drug Delivery
  
  
• Cardiology and Vascular System
  
  
• Pediatrics and Child Health
  
  
• Journal of Reproductive Medicine and Contraception
  
  
• Journal of Respiratory and Lung Disease
  
  
• Journal of Bioinformatics and Biomedicine